This proposal, a blend of basic and clinically oriented research, is based on accomplishments achieved with the aid of our MERIT Award. Specifically, the following projects are proposed. I. We plan to extend our studies (Proc. Natl. Acad. Sci., USA 95, 537, 1998) on the interactions of double-headed peptide ligands with fibrin(ogen). (i) The peptide head groups will be connected with polyethyleneglycol tethers, longer and shorter than in the previous work (n=18), so as to determine optimal length for fibrin(ogen) assembly; (ii) head group peptides will be modified (up to ca. 20 residues) to reflect the N-terminal sequence of the alpha chain in fibrin; (iii) effectiveness of the synthetic compounds for promoting fibrinogen assembly in solution will be examined by a variety of physical techniques, and (iv) their influence on clotting times will be evaluated. II. Novel screens for the rapid diagnosis of disorders of fibrin stabilization and improved measurements of Factor XIIIa activity will be developed. III. Major focus will be an in-depth analysis of autoimmune inhibitors of fibrin stabilization, based on specimens we collected over the years from hemorrhagic patients. One of the inhibitors is directed against the crosslinking sites of the alpha chains of fibrin, the others against various determinants in Factor XIII. Precise identification of epitope recognitions by these autoimmune antibodies will be carried out in order to gain better insight into the basic structure-function relationships in fibrin stabilization and also for devising affinity procedures for removing the antibodies from the patient's circulation.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL016346-29
Application #
2752377
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1993-12-05
Project End
2002-11-30
Budget Start
1999-01-01
Budget End
1999-11-30
Support Year
29
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Lefebvre, Phil; Velasco, Pauline T; Dear, Amy et al. (2004) Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). Blood 103:2571-6
Iismaa, Siiri E; Holman, Sara; Wouters, Merridee A et al. (2003) Evolutionary specialization of a tryptophan indole group for transition-state stabilization by eukaryotic transglutaminases. Proc Natl Acad Sci U S A 100:12636-41
O'Neill, Gerald M; Prasanna Murthy, S N; Lorand, Laszlo et al. (2003) Activation of transglutaminase in mu-calpain null erythrocytes. Biochem Biophys Res Commun 307:327-31
Lorand, Laszlo; Velasco, Pauline T; Hill, John M et al. (2002) Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against actor XIII. Thromb Haemost 88:919-23
Lorand, Laszlo (2002) Transglutaminase: remembering Heinrich Waelsch. Neurochem Int 40:7-12
Lorand, L (2001) Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci 936:291-311
Lorand, L (2000) Sol Sherry Lecture in Thrombosis : research on clot stabilization provides clues for improving thrombolytic therapies. Arterioscler Thromb Vasc Biol 20:9-Feb
Lorand, L; Velasco, P T; Murthy, S N et al. (1999) Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood 93:909-17
Lorand, L; Parameswaran, K N; Murthy, S N (1998) A double-headed Gly-Pro-Arg-Pro ligand mimics the functions of the E domain of fibrin for promoting the end-to-end crosslinking of gamma chains by factor XIIIa. Proc Natl Acad Sci U S A 95:537-41
Parameswaran, K N; Cheng, X F; Chen, E C et al. (1997) Hydrolysis of gamma:epsilon isopeptides by cytosolic transglutaminases and by coagulation factor XIIIa. J Biol Chem 272:10311-7

Showing the most recent 10 out of 23 publications